Cargando…

Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers

BACKGROUND: Additional accurate non-invasive biomarkers are needed in the clinical setting to improve prostate cancer (PCa) diagnosis. Here we have developed a new and improved multiplex mRNA urine test to detect prostate cancer (PCa). Furthermore, we have validated the PCA3 urinary transcript and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Mengual, Lourdes, Lozano, Juan José, Ingelmo-Torres, Mercedes, Izquierdo, Laura, Musquera, Mireia, Ribal, María José, Alcaraz, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746764/
https://www.ncbi.nlm.nih.gov/pubmed/26856686
http://dx.doi.org/10.1186/s12885-016-2127-2
_version_ 1782414858929569792
author Mengual, Lourdes
Lozano, Juan José
Ingelmo-Torres, Mercedes
Izquierdo, Laura
Musquera, Mireia
Ribal, María José
Alcaraz, Antonio
author_facet Mengual, Lourdes
Lozano, Juan José
Ingelmo-Torres, Mercedes
Izquierdo, Laura
Musquera, Mireia
Ribal, María José
Alcaraz, Antonio
author_sort Mengual, Lourdes
collection PubMed
description BACKGROUND: Additional accurate non-invasive biomarkers are needed in the clinical setting to improve prostate cancer (PCa) diagnosis. Here we have developed a new and improved multiplex mRNA urine test to detect prostate cancer (PCa). Furthermore, we have validated the PCA3 urinary transcript and some panels of urinary transcripts previously reported as useful diagnostic biomarkers for PCa in our cohort. METHODS: Post-prostatic massage urine samples were prospectively collected from PCa patients and controls. Expression levels of 42 target genes selected from our previous studies and from the literature were studied in 224 post-prostatic massage urine sediments by quantitative PCR. Univariate logistic regression was used to identify individual PCa predictors. A variable selection method was used to develop a multiplex biomarker model. Discrimination was measured by ROC curve AUC for both, our model and the previously published biomarkers. RESULTS: Seven of the 42 genes evaluated (PCA3, ELF3, HIST1H2BG, MYO6, GALNT3, PHF12 and GDF15) were found to be independent predictors for discriminating patients with PCa from controls. We developed a four-gene expression signature (HIST1H2BG, SPP1, ELF3 and PCA3) with a sensitivity of 77 % and a specificity of 67 % (AUC = 0.763) for discriminating between tumor and control urines. The accuracy of PCA3 and previously reported panels of biomarkers is roughly maintained in our cohort. CONCLUSIONS: Our four-gene expression signature outperforms PCA3 as well as previously reported panels of biomarkers to predict PCa risk. This study suggests that a urinary biomarker panel could improve PCa detection. However, the accuracy of the panels of urinary transcripts developed to date, including our signature, is not high enough to warrant using them routinely in a clinical setting. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2127-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4746764
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47467642016-02-10 Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers Mengual, Lourdes Lozano, Juan José Ingelmo-Torres, Mercedes Izquierdo, Laura Musquera, Mireia Ribal, María José Alcaraz, Antonio BMC Cancer Research Article BACKGROUND: Additional accurate non-invasive biomarkers are needed in the clinical setting to improve prostate cancer (PCa) diagnosis. Here we have developed a new and improved multiplex mRNA urine test to detect prostate cancer (PCa). Furthermore, we have validated the PCA3 urinary transcript and some panels of urinary transcripts previously reported as useful diagnostic biomarkers for PCa in our cohort. METHODS: Post-prostatic massage urine samples were prospectively collected from PCa patients and controls. Expression levels of 42 target genes selected from our previous studies and from the literature were studied in 224 post-prostatic massage urine sediments by quantitative PCR. Univariate logistic regression was used to identify individual PCa predictors. A variable selection method was used to develop a multiplex biomarker model. Discrimination was measured by ROC curve AUC for both, our model and the previously published biomarkers. RESULTS: Seven of the 42 genes evaluated (PCA3, ELF3, HIST1H2BG, MYO6, GALNT3, PHF12 and GDF15) were found to be independent predictors for discriminating patients with PCa from controls. We developed a four-gene expression signature (HIST1H2BG, SPP1, ELF3 and PCA3) with a sensitivity of 77 % and a specificity of 67 % (AUC = 0.763) for discriminating between tumor and control urines. The accuracy of PCA3 and previously reported panels of biomarkers is roughly maintained in our cohort. CONCLUSIONS: Our four-gene expression signature outperforms PCA3 as well as previously reported panels of biomarkers to predict PCa risk. This study suggests that a urinary biomarker panel could improve PCa detection. However, the accuracy of the panels of urinary transcripts developed to date, including our signature, is not high enough to warrant using them routinely in a clinical setting. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2127-2) contains supplementary material, which is available to authorized users. BioMed Central 2016-02-09 /pmc/articles/PMC4746764/ /pubmed/26856686 http://dx.doi.org/10.1186/s12885-016-2127-2 Text en © Mengual et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Mengual, Lourdes
Lozano, Juan José
Ingelmo-Torres, Mercedes
Izquierdo, Laura
Musquera, Mireia
Ribal, María José
Alcaraz, Antonio
Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers
title Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers
title_full Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers
title_fullStr Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers
title_full_unstemmed Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers
title_short Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers
title_sort using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mrna urine test and validation of current biomarkers
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746764/
https://www.ncbi.nlm.nih.gov/pubmed/26856686
http://dx.doi.org/10.1186/s12885-016-2127-2
work_keys_str_mv AT menguallourdes usinggeneexpressionfromurinesedimenttodiagnoseprostatecancerdevelopmentofanewmultiplexmrnaurinetestandvalidationofcurrentbiomarkers
AT lozanojuanjose usinggeneexpressionfromurinesedimenttodiagnoseprostatecancerdevelopmentofanewmultiplexmrnaurinetestandvalidationofcurrentbiomarkers
AT ingelmotorresmercedes usinggeneexpressionfromurinesedimenttodiagnoseprostatecancerdevelopmentofanewmultiplexmrnaurinetestandvalidationofcurrentbiomarkers
AT izquierdolaura usinggeneexpressionfromurinesedimenttodiagnoseprostatecancerdevelopmentofanewmultiplexmrnaurinetestandvalidationofcurrentbiomarkers
AT musqueramireia usinggeneexpressionfromurinesedimenttodiagnoseprostatecancerdevelopmentofanewmultiplexmrnaurinetestandvalidationofcurrentbiomarkers
AT ribalmariajose usinggeneexpressionfromurinesedimenttodiagnoseprostatecancerdevelopmentofanewmultiplexmrnaurinetestandvalidationofcurrentbiomarkers
AT alcarazantonio usinggeneexpressionfromurinesedimenttodiagnoseprostatecancerdevelopmentofanewmultiplexmrnaurinetestandvalidationofcurrentbiomarkers